The use of the theory of planned behavior to predict medication adherence in schizophrenia

Clinical Schizophrenia and Related Psychoses

Volumn 1, Issue 3, 2007, Pages 227-242

  Kopelowicz, Alex ^a,d   Wallace, Charles ^a   Liberman, Robert Paul ^a   Aguirre, Fabian ^b   Zarate, Roberto ^a   Mintz, Jim ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d San Fernando Mental Health Center   (United States)

Author keywords

Antipsychotic Medications; Hispanic; Medication Adherence; Schizophrenia; Theory of Planned Behavior

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; CONCURRENT VALIDITY; FEMALE; HUMAN; INTERNAL CONSISTENCY; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PATIENT COMPLIANCE; PSYCHOLOGICAL RATING SCALE; RELIABILITY; SCHIZOPHRENIA; TEST RETEST RELIABILITY; THEORY OF PLANNED BEHAVIOR; THEORY OF PLANNED BEHAVIOR INVENTORY; TREATMENT OUTCOME;

EID: 67649752227     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.1.3.2     Document Type: Article

References (59)

1. Weiden PJ, Olfson M, Essock S. Medication noncompliance in schizophrenia: Efects on mental health service policy. In: Blackwell B, editor. Treatment compliance and the therapeutic alliance. Amsterdam: Harwood Academic Publishers; 1997. p. 35-60.
2. Hoge SK, Appelbaum PS, Lawlor T, Beck JC, Litman R, Greer A, et al. A prospective, multicenter study of patients' refusal of antipsychotic medication. Arch Gen Psychiatry 1990;47(10):949-956.
3. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21(3):419-429.
4. Knapp M, King D, Pugner K, Lapuerta P. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry 2004;184:509-516.
5. Awad AG, Voruganti LN. New antipsychotics, compliance, quality of life, and subjective tolerability-are patients better of? Can J Psychiatry 2004;49(5):297-302.
6. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical fndings. Schizophr Bull 1997;23(4):637-651.
7. Zygmunt A, Olfson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002;159(10):1653-1664.
8. Sellwood W, Tarrier N. Demographic factors associated with extreme non-compliance in schizophrenia. Soc Psychiatry Psychiatr Epidemiol 1994;29(4):172-177.
9. Razali MS, Yahya H. Compliance with treatment in schizophrenia: a drug intervention program in a developing country. Acta Psychiatr Scand 1995;91(5):331-335.
10. Buchanan A. A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 1992;22(3):787-797.
11. Drake RE, Osher FC, Wallach MA. Alcohol use and abuse in schizophrenia. A prospective community study. J Nerv Ment Dis 1989;177(7):408-414.
12. Kashner TM, Rader LE, Rodell DE, Beck CM, Rodell LR, Muller K. Family characteristics, substance abuse, and hospitalization patterns of patients with schizophrenia. Hosp Community Psychiatry 1991;42(2):195-196.
13. Owen RR, Fischer EP, Booth BM, Cufel BJ. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv 1996;47(8):853-858.
14. Van Putten T, Crumpton E, Yale C. Drug refusal in schizophrenia and the wish to be crazy. Arch Gen Psychiatry 1976;33(12):1443-1446.
15. Bartko G, Herczeg I, Zador G. Clinical symptomatology and drug compliance in schizophrenic patients. Acta Psychiatr Scand 1988;77(1):74-76.
16. Pan PC, Tantam D. Clinical characteristics, health beliefs and compliance with maintenance treatment: a comparison between regular and irregular attenders at a depot clinic. Acta Psychiatr Scand 1989;79(6):564-570.
17. Marder SR, Mebane A, Chien CP, Winslade WJ, Swann E, Van Putten T. A comparison of patients who refuse and consent to neuroleptic treatment. Am J Psychiatry 1983;140(4):470-472.
18. McEvoy JP, Apperson LJ, Appelbaum PS, Ortlip P, Brecosky J, Hammill K, et al. Insight in schizophrenia: its relationship to acute psychopathology. J Nerv Ment Dis 1989;177(1):43-47.
19. Amador XF, Strauss DH, Yale SA, Flaum MM, Endicott J, Gorman JM. Assessment of insight in psychosis. Am J Psychiatry 1993;150(6):873-879.
20. Smith CM, Barzman D, Pristach CA. Efect of patient and family insight on compliance of schizophrenic patients. J Clin Pharmacol 1997;37(2):147-154.
21. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974;31(1):67-72.
22. Fleishhacker WW, Meise U, Gunther V, Kurz M. Compliance with antipsychotic drug treatment: infuence of side efects. Acta Psychiatr Scand Suppl 1994;382:11-15.
23. Frank AF, Gunderson JG. Te role of the therapeutic alliance in the treatment of schizophrenia. Relationship to course and outcome. Arch Gen Psychiatry 1990;47(3): 228-236.
24. Takeuchi DT, Sue S, Yeh M. Return rates and outcomes from ethnicity-specifc mental health programs in Los Angeles. Am J Public Health 1995;85(5):638-643.
25. Day JC, Bentall RP, Roberts C, Randall F, Rogers A, Cattell D, et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry 2005;62(7):717-724.
26. Becker MH. Te health belief model and sick role behavior. Health Educ Monogr 1974;2:409-419.
27. Clark NM, Becker MH. Teoretical models and strategies for improving adherence and disease management. In: Shumaker SA, Shron EB, Ocken JK, McBee WL, editors. Te handbook of health behavior change. New York: Springer Publishing Company; 1988. p.5-32.
28. Kelly GR, Mamon JA, Scott JE. Utility of the health belief model in examining medication compliance among psychiatric outpatients. Soc Sci Med 1987;25(11):1205-1211.
29. Budd RJ, Hughes IC, Smith JA. Health beliefs and compliance with antipsychotic medication. Br J Clin Psychol 1996;35(Pt 3):393-397.
30. Adams J, Scott J. Predicting medication adherence in severe mental disorders. Acta Psychiatr Scand 2000;101(2):119-124.
31. Weiden, P, Rapkin B, Mott T, Zygmunt A, Goldman D, Horvitz-Lennon M, et al. Rating of medication infu-ences (ROMI) scale in schizophrenia. Schizophr Bull 1994;20(2):297-310.
32. Babiker IE. Noncompliance in schizophrenia. Psychiatr Dev 1986;4(4):329-337.
33. Bebbington PE. Te content and context of compliance. Int Clin Psychopharmacol 1995;9(Suppl 5):41-50.
34. Erickson DH, Beiser M, Iacono WG. Social support predicts 5-year outcome in frst episode schizophrenia. J Abnorm Psychol 1998;107(4):681-685.
35. Hudson TJ, Owen RR, Trush CR, Han X, Pyne JM, Tapa P, et al. A pilot study of barriers to medication adherence in schizophrenia. J Clin Psychiatry 2004;65(2):211-216.
36. Blackwell B. Treatment adherence. Br J Psychiatry 1976;129:513-531.
37. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ. Predicting medication noncompliance afer hospital discharge among patients with schizophrenia. Psychiatr Serv 2000;51(2):216-222.
38. Fishbein M, Ajzen I. Belief, attitude, intention and behavior: an introduction to theory and research. Reading (MA): Addison-Wesley; 1975.
39. Ajzen I, Fishbein M. Understanding attitudes and predicting social behavior. Englewood Clifs (NJ): Prentice-Hall; 1980.
40. Ajzen I. Attitudes, personality, and behavior. Chicago: Dorsey Press; 1988.
41. Ajzen I. Te theory of planned behavior. Organizational Behavior and Human Decision Processes 1991;50:179-211.
42. Miller P, Wikof R, McMahon M, Garrett MJ, Ringel K, Collura D, et al. Personal adjustments and regimen compliance 1 year afer myocardial infarction. Heart Lung 1989;18(4):339-346.
43. Miller P, Wikof R, Hiatt A. Fishbein's model of reasoned action and compliance behavior of hypertensive patients. Nurs Res 1992;41(2):104-109.
44. Jarvis DA. Te role of attitudes and social norms in the compliance of chronic schizophrenics with their antipsy- chotic medications. Dissertation Abstracts International 1985;46:2065.
45. Chiurazzi JH. Schizophrenic patients' decision-making process in regard to medication treatment compliance. Dissertation Abstracts International 1987;48:258.
46. Radomsky ED. Measurement and assessment of compliance with an oral haloperidol regimen. Dissertation Abstracts International: Section B: Te Sciences & Engineering 1995;56:3461.
47. Weiden PJ, Mott T, Curcio N. Recognition and management of neuroleptic noncompliance. In: Shriqui C, Nasrallah H, editors. Contemporary issues in the treatment of schizophrenia. New York: Raven Press; 1995. p.463-485.
48. Velligan DI, Lam Y W, Glahn DC, Barrett JA, Maples NJ, Ereshefsky L, et al. Defning and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull 2006;32(4):724-742.
49. Hosch HM, Meyer LD, Barrientos GA, Fierro C, Ramirez JI, Moreno A, et al. Predicting adherence to medication by Hispanics with schizophrenia. Hispanic Journal of Behavioral Sciences 1995;17:320-333.
50. Ramirez Garcia JI, Chang CL, Young JS, Lopez SR, Jenkins JH. Family support predicts psychiatric medication usage among Mexican American individuals with schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2006;41(8):624-631.
51. Varkey L, Sathyavathi K. Locus of control and other personality variables in psychotics. Psychological Studies 1984;29:83-87.
52. Hofman H, Kupper Z, Kunz B. Hopelessness and its impact on rehabilitation outcome in schizophrenia - an exploratory study. Schizophr Res 2000;43:147-158.
53. Eckman TA, Liberman R P, Phipps CC, Blair KE. Teaching medication management skills to schizophrenic patients. J Clin Psychopharmacol 1990;10(1):33-38.
54. Byerly MJ, Tompson A, Carmody T, Bugno R, Erwin T, Kashner M, et al. Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. Psychiatr Serv 2007;58(6):844-847.
55. Velligan DI, Wang M, Diamond P, Glahn DC, Castillo D, Bendle S, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv 2007;58(9):1187-1192.
56. Guarnaccia PJ, Parra P. Ethnicity, social status, and families' experiences of caring for a mentally ill family member. Community Ment Health J 1996;32(3):243-260.
57. Jenkins JH. Subjective experience of persistent schizophrenia and depression among U.S. Latinos and Euro-Americans. Br J Psychiatry 1997;171:20-28.
58. Vega WA, Kolody B, Aguilar-Gaxiola S, Catalano R. Gaps in service utilization by Mexican Americans with mental health problems. Am J Psychiatry 1999;156(6):928-934.
59. Kamb ML, Fishbein M, Douglas JM, Rhodes F, Rogers J, Bolan G, et al. Efcacy of risk-reduction counseling to prevent human immunodefciency virus and sexually transmitted diseases: a randomized controlled trial. JAMA 1998;280(13):1161-1167.